Forty clinical isolates of Pseudomonas aeruginosa were tested for their susceptibility to cefoperazone, cefotaxime, moxalactam, piperacillin, N-formimidoyl thienamycin (MK0787), and gentamicin at three different inocula. At an inoculum of 5 x 103 colony-forming units (CFU) per ml, the mnimimnum inhibitory concentrations (in micrograms per milliliter) for 90% of isolates (MICOo) were as follows: gentamicin, 1; N-formimidoyl thienamycin, 2; cefoperazone, 4; piperacillin, 8; moxalactam, 16; and cefotaxime, 16. When the inoculum was increased to 5 x iO6 CFU/ml, the MICso for all drugs tested increased. Among the beta-lactam antibiotics, N-formimidoyl thienamycin and cefoperazone had the lowest MIC90 (8 ,ug/ml) at this inoculum. When the inoculum was increased further to 5 x 107 CFU/ml, an MICO0 could be determined only for gentamicin and N-formimidoyl thienamycin (4 and 8 jig/ml, respectively). Indeed, the MIC50 for moxalactam, cefotaxime, cefoperazone, and piperacillin was 128 ,ig/ml or more at this inoculum. The minimum bactericidal concentration for 90% of isolates (MBCs0) at an inoculum of 5 x 105 CFU/ml ranged from 8 ,ig/ml for gentamicin and Nformimidoyl thienamycin to 128 ,tg/ml for cefotaxime. At the highest inoculum, however, whereas the MBCso for gentamicin and N-formimidoyl thienamycin remained at 8 ,ug/ml, the MBC9o for each of the other drugs was >128 jig/ml. NFormimidoyl thienamycin was the only drug tested for which an MICloo and MBCioo (MIC and MBC for 100% of isolates) could be determined, and these were not significantly different from the MICs0 and MBCs0.
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A number of recently developed beta-lactam antibiotics, including piperacillin (2) , cefoperazone (5) , cefotaxime (9) , moxalactam (1) , and the structurally novel N-formimidoyl thienamycin (MK0787) (6) , have displayed significant activity against Pseudomonas aeruginosa in vitro and in this respect are clearly different from the currently available representatives or other recently introduced members of this compound class. Since the activities of beta-lactam antibiotic derivatives are usually impaired by large inocula, it seemed important to determine whether all of the agents that exhibited this remarkable activity against P. aeruginosa share this liability or whether some more closely resemble those aminoglycosides whose activity is not influenced by large inocula. The results of such a study are recorded in this report.
MATERIALS AND METHODS
Organism. Forty conventionally characterized (4) isolates of P. aeruginosa from the blood or urine of patients at the Kings County and Brooklyn Jewish hospitals were used in this study. All 2). This close relationship between the MIC and MBC for N-formimidoyl thienamycin remained constant throughout the ranges of inocula tested. There were fourfold and eightfold spreads between the MICs and MBCs of cefotaxime and cefoperazone at an inoculum of 5 x 105 CFU/ml, respectively (Tables 1 and 2 ). The dimensions of the divergence of the MBC and MIC at an inoculum of 5 x 107 could not be determined for piperacillin, cefotaxime, cefoperazone, and moxalactam since neither MIC nor MBC endpoints were obtained with most isolates. It was interesting to note that only N-formimidoyl thienamycin exhibited an MIC,oo or MBC,oo at a concentration of 16 ,ig/ml at an inoculum of 5 x 107 CFU/ml. The MIC,oo of all other drugs, including gentamicin, was 64 yg/ml or more, even at an inoculum of 5 x 105 CFU/ ml.
DISCUSSION
Carbenicillin was the first of the beta-lactam antibiotics to exhibit significant activity against P. aeruginosa. The activity of carbenicillin against some isolates of this organism was marginal and was regularly reduced by inocula of 106 CFU/ml or greater (1).
The newer, broad-spectrum beta-lactam antibiotics cefotaxime, cefoperazone, moxalactam, and piperacillin offer a wide spectrum and are more active than carbenicillin against P. aeruginosa (1, 2, 5, 7, 9). However, like carbenicillin, the activities of piperacillin (2, 8) , cefotaxime (1), and moxalactam (1), as well as of azlocillin and mezlocillin (3), two other new beta-lactam antibiotics, are reduced with increases in inoculum size. Our data confirm these findings for piperacillin, moxalactam, and cefotaxime and also show that such an effect exists for cefoperazone. At an inoculum of 5 x 107 CFU/ml, virtually all isolates tested had an MIC well above the therapeutic range of these four drugs (Table 1) .
N-Formimidoyl thienamycin was as active or more active than the other beta-lactam antibiotics at an inoculum of 5 x 103 CFU/ml. This compound differed significantly, however, from the other beta-lactam antibiotics in that its activity against P. aeruginosa was not affected by increases in inoculum size. For the few isolates which exhibited more than a fourfold rise in MICs when the inoculum was increased, N-formimidoyl thienamycin was still effective at 8 ,ug/ ml or less at an inoculum of 5 x 107 CFU/ml, a concentration which is attainable in the serum (Merck Sharp & Dohme, unpublished data). At no inoculum was there a great difference between the MIC and MBC of N-formimidoyl thienamycin. In this respect, this thienamycin derivative resembled gentamicin more than it resembled other beta-lactam antibiotics.
